ChromaDex Shares Promising Findings from Clinical Study Demonstrating Oral Supplementation with Nicotinamide Riboside (NR) Increased Nicotinamide Adenine Dinucleotide (NAD+) Levels in the Brain and Positively Impacted Neurodegenerative Biomarkers

LOS ANGELES--(BUSINESS WIRE)---- $CDXC #NAD--ChromaDex Corp. (NASDAQ:CDXC), a global bioscience company dedicated to healthy aging, announced promising new findings based on a previously published clinical trial of company’s proprietary Niagen® ingredient (patented nicotinamide riboside or NR), which was supported by the ChromaDex External Research Program (CERP™). The new study, published...

Click to view original post